Clinical Trial

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
Protocol Amendment History 5 changes
notable Trial sites expanded: 635 -> 643 locations 2026-07-31
notable Trial sites expanded: 618 -> 635 locations 2026-07-09
notable Trial sites expanded: 559 -> 618 locations 2026-06-11
notable Trial sites expanded: 492 -> 559 locations 2026-05-19
notable Trial sites expanded: 72 -> 492 locations 2026-05-06
Trial Details
NCT Number NCT07517263
Lead Sponsor Novartis Pharmaceuticals
Conditions Cardiovascular Disease and Lipoprotein(a)
Enrollment 5,700 participants
Start Date 2026-05-11
Primary Completion 2030-01-09 (estimated)
Study Completion 2030-01-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-30